Pfizer and BioNTech have announced that they will be partnering with the U.S. Government to provide more COVID-19 Vaccines.

The best part? It’s funded by American taxpayers.

Pfizer and BioNTech announced a new vaccine supply agreement with the U.S. government to “support the continued fight against COVID-19.”

The U.S. government will be receiving 105 million doses. 

This may include “Omicron-adapted” COVID-19 vaccines for adults, subject to authorization from the U.S. Food and Drug Administration (FDA).

The doses are planned to be delivered as soon as the end of this summer and continue into the 4th quarter of this year.

PAY UP AMERICA!

The U.S. government will be paying the pharmaceutical companies a hefty $3.2 billion upon receiving the first 105 million doses. Under this agreement, the U.S. government also has the option to purchase up to 195 million additional doses, bringing the total number of potential doses to 300 million.

“As the virus evolves, this new agreement will help ensure people across the country have access to vaccines that may provide protection against current and future variants,” said Albert Bourla, Chairman and Chief Executive Officer, Pfizer. “

Vaccines have been and will remain critical to protecting people of all ages against COVID-19. We remain proud of our long-term partnership with the U.S. government in helping to address this pandemic, and of the ongoing impact of vaccination efforts in the U.S. and around the world.”

The Pfizer-BioNTech COVID-19 Vaccine, which is based on BioNTech’s proprietary mRNA technology, was developed by BioNTech and Pfizer and funded by the U.S. Government.

The Pandemic Isn’t Over Yet!

“This agreement will provide additional doses for U.S. residents and help cope with the next COVID-19 wave. Pending regulatory authorization, it will also include an Omicron-adapted vaccine, which we believe is important to address the rapidly spreading Omicron variant,” said Sean Marett, Chief Business and Chief Commercial Officer of BioNTech. “We appreciate the continued partnership of the U.S. government in our shared goal to help end this pandemic.”

Pfizer-BioNTech COVID-19 Vaccine is FDA authorized under Emergency Use Authorization (EUA) for active immunization to prevent coronavirus disease 2019 (COVID-19) caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) in individuals 6 months of age and older.

The global pharmaceutical Industry raked in over $1.27 TRILLION U.S. dollars in 2020.

The COVID pandemic proved to be a very lucrative opportunity for the pharmaceutical industry.

Add comment